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ABSTRACT
Poly(ADP-Ribose) (PAR) polymerase (PARP) inhibi-
tors represent a promising class of novel anticancer
agents. The present study explores the molecular
rationale for combining veliparib (ABT-888) with
camptothecin (CPT) and its clinical derivatives,
topotecan and irinotecan. ABT-888 inhibited PAR
induction by CPT and increased CPT-induced cell
killing and histone cH2AX. Increased DNA breaks
by ABT-888 were not associated with a correspond-
ing increase of topoisomerase I cleavage complexes
and were further increased by inactivation of tyrosyl-
DNA phosphodiesterase 1. SiRNA knockdown for
the endonuclease XPF–ERCC1 reduced the ABT-
888-induced cH2AX response in non-replicating and
replicating cells but enhanced the antiproliferative
effect of ABT-888 in CPT-treated cells. Our findings
indicate the involvement of XPF–ERCC1 in inducing
cH2AX response and repairing topoisomerase
I-induced DNA damage as an alternative pathway
from PARP and tyrosyl-DNA phosphodiesterase 1.
INTRODUCTION
DNA topoisomerase I (Top1) is the target of clinically
approved anticancer agents (topotecan, irinotecan and
belotecan) derived from the plant alkaloid camptothecin
(CPT) (1–4). It is essential in metazoans for the relaxation
of DNA supercoiling generated during transcription and
replication. Relaxation proceeds by formation of Top1
cleavage complexes (Top1cc), in which one DNA strand
is cleaved by the covalent linkage of Top1 to the 30-end
of a DNA phosphodiester bond [reviewed in (3–6)].
Top1cc are normally very transient. Following DNA re-
laxation, Top1 is released by religation of the DNA.
Top1cc can be stabilized (or ‘trapped’) under at least
three conditions (2): (i) by drugs such as CPTs and
non-CPT Top1 inhibitors (3,7); (ii) when the DNA
template is altered (2); and (iii) during apoptosis (8).
Abnormally stabilized Top1cc can be highly damaging
when they interfere with the movement of replication
and transcription complexes (9–12). Such collisions
convert the Top1cc into DNA double-strand ends (DSE)
with Top1 remaining covalently attached to the 30-end of
the broken DNA.
The repair of Top1-associated DNA damage in human
cells is not fully understood (2). In budding yeast, two
main pathways can remove Top1 adducts: hydrolysis of
the Top1–DNA bond by tyrosyl–DNA phosphodiesterase
1 (TDP1) (13–15), and endonucleolytic excision of the
Top1cc along with a section of the covalently attached
DNA segment by different endonuclease complexes
including Rad1–Rad10, Mre11–Rad50–Xrs2, Mus81–
Mms4 and Slx1–Slx4 (2,16–18). The redundancy
between the TDP1 and the endonuclease pathways has
been demonstrated in yeast where inactivation of TDP1
has minimal impact on CPT action unless the Rad1–
Rad10 endonuclease is simultaneously inactivated
(16–18). Rad1–Rad10 is the heterodimeric ortholog of
the human endonuclease XPF–ERCC1 (19). Those endo-
nucleases cleave the duplex DNA segment immediately
50 from the damaged region where the two DNA strands
are separated (30-ﬂap, splayed arm or bubble) (19). XPF–
ERCC1 is also a critical 50-endonuclease in nucleotide
excision repair (NER) both for global and transcription-
coupled repair (TCR) (20).
A role for poly(ADP-ribose) polymerase (PARP) in
the repair of Top1-associated DNA damage is
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mammalian cells to CPT (21–23); PARP inhibitors
enhance the effects of CPT and its clinical derivatives
both in cell culture (22,24–30) and in xenograft systems
(29,30). However, the molecular mechanisms by which
PARP acts in the repair of Top1-induced DNA damage
have not been elucidated and yeast cannot be used because
the PARP pathway is not present in yeast cells. In mam-
malian cells, PARP inhibitors increase DNA breaks in
response to Top1cc (22,24,27) but without concomitant
increase in Top1–DNA complexes (27). PARP inactiva-
tion is associated with Tdp1 deﬁciency (2) and with toxic
interference of Ku and DNA-PK in the homologous
recombination (HR) pathway (23), which is critical for
the repair of Top1cc (17,23,31–36).
The purpose of the present study is to elucidate the
molecular mechanisms involved in the sensitization of
cancer cells to CPT by PARP inhibitors. For this
purpose, we used veliparib (ABT-888), one of the
leading PARP inhibitors in clinical development (37,38).
ABT-888 is a benzimidazole derivative with high potency
against both PARP-1 and PARP-2 enzymes (Ki=5nM)
(28). ABT-888 is orally bioavailable (39) and in clinical
trials in combination with temozolomide, cyclophospha-
mide, platinum derivatives (cis-platin and oxaliplatin),
mitomycin, radiation therapy and CPT derivatives
(irinotecan and topotecan) ( http://clinicaltrialsfeeds.org/
clinical-trials/results/term=Drug:+veliparib+(ABT-888)?
recr=Open). Our study examines the molecular effects of
ABT-888 on CPT-induced cytotoxicity and gH2AX
response, and the role of XPF–ERCC1 in the repair of
Top1cc-induced DNA damage, which is relevant to the
ongoing clinical trials combining ABT-888 with CPT
derivatives.
MATERIALS AND METHODS
Cell lines and drugs
Human U2OS osteosarcoma cells and human HT29 colon
carcinoma cells were obtained from the Developmental
Therapeutics Program (DTP, National Cancer Institute,
Bethesda, MD, USA) and maintained in RPMI 1640
medium complemented with 10% fetal bovine serum
(FBS) at 37 C, 5% CO2. Human peripheral lymphocytes
were obtained from the Blood Bank at the National
Institutes of Health and maintained in RPMI 1640 sup-
plemented with 10% FBS. CPT, veliparib (ABT-888,
Abbott Laboratories, Abbott Park, IL, USA) and
ﬂavopiridol (FLV) were obtained from the Drug
Synthesis and Chemistry Branch, Division of Cancer
Treatment (National Cancer Institute, Bethesda, MD,
USA). 5,6-dichlorobenzimidazole 1-b-D-ribofuranoside
(DRB) and the proteasome inhibitor, MG-132 were
obtained from Sigma (St Louis, MO, USA). TDP1
+/+
and TDP1
 /  murine embryonic ﬁbroblasts (MEFs) (40)
were a kind gift from Dr. Cornelius F. Boerkoel (Center
for Molecular Medicine and Therapeutics; University of
British Columbia, Canada).
Cytotoxicity assay
The ATPlite assay (PerkinElmer Life Sciences, Waltham,
MA, USA) was used to determine the cytotoxicity of CPT
in the absence or presence of ABT-888. The ATP level in
untreated cells was deﬁned as 100%. Survival of treated
cells was deﬁned as ATP treated cells/ATP untreated cells 100.
Western blotting
Proteins were detected by western blotting with corres-
ponding speciﬁc primary antibodies. XPF monoclonal
antibody (Ab-1) was purchased from Lab Vision,
Thermo Fisher Scientiﬁc, Fremont, CA, USA, ERCC1
monoclonal antibody (D-10) from Santa Cruz
Biotechnology, Santa Cruz, CA, b-actin monoclonal
antibody (A5441) from Sigma, anti-phosphorylated-
H2AX (gH2AX, clone JBW301) from Upstate Biotech,
Millipore, Billerica, NY, USA and GAPDH monoclonal
antibody (14C10) from Cell signaling Technology,
Danvers, MA, USA. The ﬁgures show representative data
that were reproducible in separate experiments.
COMET assays
DNA double-strand breaks (DSBs) were evaluated using
the neutral single cell gel electrophoresis (neutral COMET
assay). The COMET assays were performed according to
the manufacturer’s instructions (Trevigen, Gaithersburg,
MD, USA). Data are expressed as mean±SD.
Immunoﬂuorescence assays
Cells plated in 4-well chamber slides (Nalgene Nunc
International, Rochester, NY, USA) and cytospins of
human lymphocytes were processed for immunoﬂuores-
cence microscopy as described (41). For the simultaneous
detection of g-H2AX and replication foci, cells were
labeled with 30mmol/l 5-ethenyl-20-deoxyuridine (EdU,
Invitrogen, Carlsbad, CA, USA) for 90min. During the
last 30min, cells were treated with CPT in the absence or
presence of ABT-888. Following treatment, the medium
was aspirated out and the cells were washed in phosphate
buffer saline (PBS). Cells were immediately ﬁxed and
permeabilized by a 20-min incubation at room tempera-
ture with 4% paraformaldehyde and an overnight incuba-
tion in ice-cold 70% ethanol at 4 C. The staining for
gH2AX was done ﬁrst as described (41). EdU staining
was then done with the Click-iT EdU Alexa Fluor 647
ﬂow cytometry assay kit from Invitrogen following the
manufacturer’s instructions. The primary antibody for
gH2AX (clone JBW301) was from Upstate (Millipore).
The anti-PAR polymer rabbit polyclonal antibody was
the product of Trevigen (Gaithersburg, MD, USA). The
anti-53BP1 antibody (NB100-904) was from Novus
Biologicals (Littleton, CO, USA).
cH2AX ﬂow cytometry
Human lymphocytes were processed for ﬂow cytometry as
described (12) using the anti-gH2AX antibody (ab11174)
from Abcam (Cambridge, MA, USA) and a Becton
Dickinson FACScan ﬂow cytometer (BD Biosciences,
San Jose, CA, USA). Percentages of gH2AX positive
3608 Nucleic Acids Research, 2011,Vol.39, No. 9cells were determined using CellQuest software (BD
Biosciences).
Alkaline elution assay
DNA damage was detected using alkaline elution assays
as described earlier (42,43). Brieﬂy, cells were radiolabeled
with [
3H]-thymidine (1.0mCi/ml) for 72h and chased
overnight (16 h) with radioisotope-free medium before
receiving drug treatments. Cells were treated as indicated;
after which, they were harvested by scraping into ice-cold
Hank’s balanced salt solution (HBSS). Total DNA breaks
[DNA strand breaks (SB)] were detected using DNA-
denaturing conditions (pH 12.1) under deproteinizing
conditions. To assess DNA–protein cross-links (DPC),
cells were treated as indicated followed by irradiation
with 30Gy to break the DNA. Samples were lysed
and evaluated for binding of the protein-crosslinked
DNA by its retention on a 0.8mm polyvinyl chloride/
acrylic copolymer. Following alkaline elution, ﬁlters
were incubated at 65 C with 1M HCl for 45min and
0.04M NaCl was added for an additional 45min of incu-
bation. Radioactivity in each fraction was measured
by liquid scintillation (Packard Instruments, Meridien,
CT, USA).
Cellular Top1–DNA complexes detection (ICE Bioassay)
Top1–DNA complexes were detected as described earlier
(43). Brieﬂy, cells were pelleted and immediately lysed in
1% sarkosyl after drug treatment. Following homogeniza-
tion with a Dounce homogenizer and pestle B, cell lysates
were gently layered on cesium chloride step gradients and
centrifuged at 165000g for 20h at 20 C. Half-milliliter
fractions were collected and the fractions 6–10 were
pooled together. The pooled fractions were then diluted
with 25mmol/l sodium phosphate buffer (pH 6.5) to make
a1  ,2  ,4  ,o r8   scaled dilution for better resolution
of differences and applied to Immobilon-P membranes
(Millipore) in a slot-blot vacuum manifold. Top1–DNA
complexes were detected using the C21 Top1 monoclonal
antibody (gift from Yung-Chi Cheng, Yale University,
New Haven, CT, USA) using standard western blotting
procedures.
siRNA transfection
Gene-speciﬁc siRNAs for XPF (L-019946-00) or ERCC1
(L-006311-00) were products of Dharmacon (Lafayette,
CO, USA). About 50nM siRNAs were transfected to
U2OS cells with Dharmafect transfection reagent
(Dharmacon) for 48h according to manufacturer’s
instructions. Then culture medium was removed and
cells were treated with CPT in the absence or presence
of ABT-888. Cells transfected with negative control
siRNA (D-001810-10, Dharmacon) were used as control.
Clonogenic assay
After drug treatment, cells were plated at a density of 100,
1000 and 10000 per well in six-well plates and incubated
for 10 days to allow formation of colonies. Cells were ﬁxed
with methanol, stained with 0.1% crystal violet (Sigma)
for 30min and washed with distilled water. Colonies were
counted after air drying. Plating efﬁciency (PE) was
deﬁned as the number of colonies counted/the number
of cells seeded. The survival fraction (SF) of untreated
negative siRNA-transfected cells was deﬁned as 100. SF
were calculated as: PE treated/PE untreated 100.
Statistical analyses
The data are represented as mean±SD or mean±SEM.
The signiﬁcance of differences between means was assessed
by the Student’s t-test, with P<0.05 being considered
statistically signiﬁcant. Three-way ANOVA tests were per-
formed to compare the difference between gH2AX levels in
individual CPT-treated cells in the presence or absence of
ABT-888 (Figure 3 and Supplementary Figure S4A).
Four-way ANOVA tests were used to compare the differ-
ence of gH2AX enhancement in si-XPF and si-Negative
cells (Figure 7 and Supplementary Figure S4B).
RESULTS
Induction of poly(ADP-ribosyl)ation by CPT
First, we tested PAR levels in CPT-treated human cancer
cells and the inhibitory effect of ABT-888 on CPT-treated
cells. In both human colon cancer HT-29 cells (Figure 1A)
and human osteosarcoma U2OS cells (Supplementary
Figure S1), PAR polymer levels increased after 30-min
CPT treatments. This PAR response was inhibited
by ABT-888, which demonstrates rapid PAR induction
by Top1 inhibition with CPT and efﬁcient inhibition by
ABT-888.
The PARP inhibitor ABT-888 (Veliparib) increases
CPT-induced cytotoxicity and DNA breaks without
increasing CPT-induced Top1cc
Next, we determined the effect of ABT-888 on the cyto-
toxicity of CPT by treating HT-29 cells with CPT in the
presence or absence of ABT-888. The results shown in
Figure 1B demonstrate that ABT-888 potentiates the cyto-
toxicity of CPT under conditions where ABT-888 (0.5mM)
had no detectable cytotoxicity (data not shown). With
30-min exposure of CPT in the presence of ABT-888,
the molecular marker of DNA DSB (44), gH2AX was
increased by ABT-888 in CPT-treated cells (Fig.1C).
Neutral COMET assays also showed increased CPT-
induced DSBs in the presence of ABT-888 (Figure 1D).
Upon CPT removal, those DSBs were more persistent
than in the absence of ABT-888 (Figure 1D). Taken
together, these experiments demonstrate increased DSBs
induced by CPT in the presence of the PARP inhibitor
ABT-888. They also show enhancement of the
CPT-induced gH2AX response.
To investigate the mechanism(s) by which ABT-888
enhances CPT-induced DNA damage, we measured
CPT-induced Top1cc as DNA–protein crosslinks (DPC)
by alkaline elution (42,43) and by the ICE-bioassay (43).
Figure 2A shows a representative experiment in which
DPC and DNA strand breaks (SB) were measured in the
same cells. Consistent with the COMET assays, ABT-888
Nucleic Acids Research,2011, Vol.39, No. 9 3609Figure 1. Potentiation of CPT-induced DNA damage by the PARP inhibitor ABT-888 in human colon cancer HT-29 cells. (A) Fluorescence images
of PAR. Cells were treated with 1mM CPT for 30min in the absence or presence of ABT-888 (0.5mM). Nuclei were labeled with PI (gray signals in
the Merge images) and PAR polymers are shown as white dots. Bar=8mm. Right, PAR quantitation (mean values±SD) using untreated Control
set as one. (B) Cytotoxicity assays. Cells were treated with CPT for 72h in the absence or presence of ABT-888 (0.5mM). The survival of untreated
cells was deﬁned as 100%. Data are shown as mean values±SD (n=3). (C) Enhancement of CPT-induced gH2AX by ABT-888. Cells were treated
with CPT for 30min in the presence or absence of ABT-888 (0.5mM). gH2AX was determined by Western blotting: Top: representative experiment;
Bottom: gH2AX levels were quantiﬁed from three independent experiments (mean values±SD) using CPT-induced gH2AX levels set as one
(**P<0.01). (D) DSB measured by neutral COMET assays. Cells were co-treated with CPT and ABT-888 for 30min; R300: cells were examined
30min after CPT removal in the absence or presence of ABT-888 (0.5mM). Left, representative images; Right top: treatment schedule; Right bottom:
quantitation of average tail lengths. At least 50 cells were quantiﬁed in each data set. Data are shown as mean values±SD. Standard t-tests were
used for statistical analyses; **P<0.01.
3610 Nucleic Acids Research, 2011,Vol.39, No. 9increased the frequency of DNA SB (Figure 2A, left
panel). Noticeably, under these conditions, the DPC
remained at the same frequency in the presence of
ABT-888 as in its absence (DPC; Figure 2A, right
panel). Similarly, ICE-bioassays showed similar levels of
Top1cc in the absence and presence of ABT-888 not only
in HT29 cells, but also in U2OS osteosarcoma cells, and
normal human peripheral lymphocyte cells (Figure 2B).
Together these results demonstrate that PARP inhibition
by ABT-888 induces the formation of additional DNA
breaks in response to CPT without increasing Top1cc.
Enhancement of both replication-dependent and
independent cH2AX by ABT-888
Because CPT-induced DNA damage results from both
replication (10,11,45,46) and transcription interference
(2,8,12,47–49), we tested the relationship between the
ABT-888-induced gH2AX and DNA replication.
Immunoﬂuorescence microscopy was used to quantitate
the gH2AX ﬂuorescent signals in individual cells
(Supplementary Figure S2A) (45,50). The distribution of
gH2AX levels showed two groups of cells with low and
high gH2AX levels, respectively. In the CPT+ABT-888
Figure 2. ABT-888 induces DNA breaks without increasing CPT-induced Top1cc. (A) Representative alkaline elution assays in HT-29 cells; Left,
CPT-induced SB under DNA denaturing conditions. Ionizing radiation (3Gy) was used as positive control. Cells were exposed to either ionizing
radiation or 1mM CPT in the presence or absence of ABT-888 (0.5mM), or were left untreated; Right, CPT-induced DPC. Cells were treated with
1mM CPT for 30min in the presence or absence of ABT-888 (0.5mM) followed by irradiation with 30Gy. DPC were measured by DNA retention on
protein-adsorbing ﬁlters. (B) Top1cc measured by ICE-bioassay in three different cell lines. HT-29 cells (top left) or U2OS cells (top right) were
treated with 1mM CPT for 30min in the presence or absence of ABT-888 (0.5mM). Human peripheral lymphocytes require higher drug concentra-
tions to elicit signals and were treated with 20mM CPT for 2h with or without ABT-888 (5mM) (bottom left). Quantitation of the lack of signiﬁcant
effect of ABT-888 on CPT-induced Top1cc in three cell lines (bottom right). For each cell line, fold change was deﬁned as Top1cc (CPT+ABT-888)/
Top1cc (CPT alone). Data are mean values±SD (n=3).
Nucleic Acids Research,2011, Vol.39, No. 9 3611treated-cells, both peaks were shifted to the right,
demonstrating the levels of gH2AX were increased by
PARP inhibition in both groups (Supplementary
Figure S2B). To clarify whether those two groups were
related to DNA replication, EdU incorporation (51) was
used to detect the replicating cells and gH2AX co-staining
was used to observe the relationship between DNA syn-
thesis and gH2AX induction (52). Figure 3A demonstrates
the induction of gH2AX foci both in replicating cells
(EdU positive) and in non-replicating cells (EdU
negative cells, indicated by arrows). EdU positive cells
presented higher levels of gH2AX than EdU negative
cells (Figure 3B), suggesting high gH2AX levels corres-
pond to replicating cells. ABT-888 induced more and
larger CPT-induced gH2AX foci in both EdU positive
(replicating) and EdU negative (non-replicating) cells
(Figure 3A and B). These results were reproducible in an
independent experiment (Supplementary Figure S4A).
ANOVA analysis of the data from two independent experi-
ments indicated signiﬁcant difference between CPT and
CPT+ABT-888 in EdU negative cells (P<0.001), and
EdU positive cells (P<0.001). Noticeably, CPT-induced
Figure 3. ABT-888 enhances both replication-dependent and independent gH2AX induced by CPT. Human osteosarcoma U2OS cells were treated
with CPT (1mM) for 30min in the presence or absence of ABT-888 (0.5mM). (A) The ﬂuorescent thymidine analog EdU was used to identify S-phase
cells by labeling their DNA (red signal). gH2AX is shown in green signal and nuclei labeled with DAPI are in blue. Representative immunoﬂuor-
escence images (bar=5mm). White arrows indicate EdU negative but gH2AX positive cells. (B) Scattered-dot plot derived from the analyses of
gH2AX level in individual cells in one representative experiment (see Supplementary Figure S4 for an independent experiment). Mean values±SEM
are shown as black bars. Number of cells analyzed: EdU-/CPT: n=67; EdU+/CPT: n=42; CPT+ABT: n=46 (EdU+), n=60 (EdU-). Standard
t-tests were used for statistical analyses of the data from the representative experiment, **P<0.01; (C) Distribution of gH2AX foci numbers per EdU
negative cells in the presence and absence of ABT-888. Dotted curves link the edges of columns (Light blue, CPT alone; Dark blue, CPT+ABT-888).
(D) Percentage distribution based on EdU and gH2AX showing gH2AX enhancement in EdU negative cells.
3612 Nucleic Acids Research, 2011,Vol.39, No. 9gH2AX in the EdU negative cell population was aug-
mented from 16% (16 out of 100 cells) for CPT alone to
42% (46 out of 110 cells) for the combination CPT+ABT-
888 (Figure 3C). Moreover, ABT-888 almost doubled the
average CPT-induced gH2AX foci per cell (26±16
for CPT alone versus 45±13 for CPT+ABT-888)
(Figure 3D). Taken together, those data demonstrate that
PARP inhibition enhances CPT-induced gH2AX both in
replicating cells and non-replicating cells.
Enhancement of transcription-related cH2AX by ABT-888
in non-replicating cells
To further elucidate the replication-independent effects of
ABT-888, we tested human peripheral lymphocytes
treated with CPT, which we previously reported induce
transcription-induced DSBs in response to CPT (12,49).
Immunoﬂuorescence imaging of gH2AX and analyses of
the number of gH2AX foci, showed a signiﬁcant increase
in gH2AX foci in the presence of ABT-888 (5.1±3.2 foci/
cell versus 1.3±1.2 foci/cell for CPT alone) (Figure 4A).
Those gH2AX foci were co-localized with p53 binding
protein 1 (53BP1), consistent with the formation of
DSBs (Figure 4B). Flow cytometry also showed  2-fold
increased gH2AX in the presence of ABT-888 (Figure 4C).
These data, together with those obtained in Figure 3
indicate that PARP inhibition enhances both CPT-
induced replication-dependent and independent DNA
damage.
Next we tested whether the effect of ABT-888 in non-
replicating cells was transcription-linked. Lymphocytes
were pretreated with transcription inhibitors before the
addition of CPT with or without ABT-888. The transcrip-
tion inhibitors DRB and FLV (8,12,49) not only
Figure 4. Enhancement of gH2AX by ABT-888 in non-replicating human peripheral blood lymphocytes. Lymphocytes were treated with CPT
(20mM) for 2h in the absence or presence of ABT-888 (5mM). (A) Top: gH2AX foci induction observed by confocal microscope; Bottom: single
cell analysis of the distribution of gH2AX foci numbers. (B) Co-localization of gH2AX and 53BP1. (C) gH2AX response determined by 2D
ﬂow-cytometry. (D) Inhibition of the gH2AX enhancement by transcription inhibitors. Lymphocytes were pretreated for 1h with DRB (100mM)
or FLV (1mM) before the addition of CPT and ABT-888. Left: representative images of gH2AX foci by confocal microscopy. Middle: average
gH2AX level per nucleus. Mean and SD from three experiments are shown. Standard t-tests were used for statistical analyses; *P<0.05 versus CPT,
**P<0.01 versus CPT, ##P<0.01 versus CPT+ABT-888. Right: fold induction of CPT-induced gH2AX by ABT-888. Fold change was deﬁned as
gH2AX (CPT+ABT-888)/gH2AX (CPT). ##P<0.01.
Nucleic Acids Research,2011, Vol.39, No. 9 3613prevented CPT-induced gH2AX (12), but also reduced the
enhancement of the CPT-induced gH2AX by ABT-888
(Figure 4D). These results demonstrate the involvement
of PARP in the repair of transcription-linked DNA
damage induced by CPT.
PARP is involved in a common repair pathway with
TDP1
Because TDP1 represents a major pathway for the repair
of Top1cc (2,15), the effects of ABT-888 were examined in
TDP1 knockout cells (40). Figure 5 (panels A and B)
shows a more intense CPT-induced gH2AX response in
the TDP1 knockout cells than the corresponding wild-type
cells (53), which is consistent with the defective repair of
Top1cc and increased DNA breaks in TDP1-deﬁcient cells
(40,43,54,55). Notably, ABT-888 failed to further enhance
the gH2AX response in the TDP1
 /  cells, which indicates
that PARP inhibition no longer enhances Top1-induced
DNA damage once TDP1 is inactivated. The effects of
ABT-888 on CPT-induced cytotoxicity were also
measured in TDP1
 /  cells. Figure 5C shows that ABT-
888 was unable to potentiate the cytotoxicity of CPT in
the TDP1
 /  cells. These data suggest that PARP acts in
the same pathway as TDP1 for the repair of Top1cc.
Because the repair of Top1cc requires the proteasomal
degradation of Top1 following its ubiquitination (46,48),
we tested whether the enhancement of gH2AX by
ABT-888 was dependent on the proteasome. Cells
treated with CPT and ABT-888 in the presence of the
proteasome inhibitor, MG-132, failed to induce gH2AX
(Supplementary Figure S3) demonstrating that PARP acts
downstream from the proteasome for the repair of Top1–
DNA complexes.
The XPF–ERCC1 complex is involved in the repair of
CPT-induced DNA damage
Based on our ﬁnding that ABT-888 induces the formation
of DNA breaks in response to CPT (see above), and on
the genetic data from yeast showing the importance of the
endonuclease Rad1–Rad10 complex as an alternative
pathway for the repair of Top1-induced DNA damage
(‘Introduction’ section), we tested the possible implication
of the mammalian Rad1–Rad10 ortholog XPF–ERCC1
complex in the repair of CPT-induced DNA damage.
Knocking-down XPF by siRNA resulted in a marked at-
tenuation of the gH2AX enhancement by ABT-888
(Figure 6A, C and D). Similar results were observed by
knocking down the DNA binding partner of XPF,
ERCC1 (Figure 6B). Notably, we found that knocking
Figure 5. TDP1-dependent enhancement of gH2AX by ABT-888. (A) Representative immunoﬂuorescence images of gH2AX in wild-type (WT) MEF
or TDP1
 /  MEF cells treated with CPT (1mM) for 30min with or without ABT-888 (0.5mM). (B) Quantitation of gH2AX levels per cell. The
average gH2AX level in CPT-treated WT cells was deﬁned as one. Data are mean values±SD. Standard t-tests were used for statistical analyses;
**P<0.01; NS, no signiﬁcant difference. (C) Cytotoxicity of CPT with or without ABT in WT and TDP1
 /  cells. MEF cells were treated with CPT
for 72h in the absence or presence of ABT-888 (0.5mM). The survival of untreated WT cells was deﬁned as 100%. Data are mean values±SD
(n=3 independent experiments).
3614 Nucleic Acids Research, 2011,Vol.39, No. 9down XPF also reduced ERCC1 expression and vice versa
(data not shown) suggesting the cross-stabilization of XPF
and ERCC1. Immunoﬂuorescence microscopy conﬁrmed
that XPF knockdown blocked the enhancing effect of
ABT-888 on the CPT-induced gH2AX formation
(Fig. 6C and D). XPF knockdown had no effect on the
gH2AX level of untreated or ABT-alone-treated cells
(data not shown). Together, these experiments
demonstrate that the enhancement of CPT-induced
gH2AX by PARP inhibition is dependent on XPF–
ERCC1.
Clonogenic assays were performed to determine the
functional implication of XPF–ERCC1 in the repair of
CPT-induced DNA damage in the absence and presence
of ABT-888. Figure 6E shows that XPF-inactivation
sensitized cells to CPT and that ABT-888 increased the
Figure 6. Involvement of XPF–ERCC1 and PARP in CPT-induced gH2AX and cytotoxicity. XPF or ERCC1 siRNAs were transfected into U2OS
cells for 48h before CPT treatment (1mM for 30min) in the presence or absence of ABT-888 (0.5mM). (A) Effect of XPF knockdown on the gH2AX
enhancement by ABT-888. gH2AX levels were detected by western blotting. XPF siRNA knockdown efﬁciency was determined as mean values±SD
(n=4). (B) Effect of ERCC1 knockdown on the gH2AX enhancement by ABT-888. gH2AX levels were detected by western blotting. ERCC1 siRNA
knockdown efﬁciency was determined as mean values±SD (n=4). (C) Representative gH2AX immunoﬂuorescence images in XPF
siRNA-transfected cells. (D) Fold induction of CPT-induced gH2AX by ABT-888. Results were from western blotting and immunoﬂuorescence
assays, respectively. Data are mean values±SD (n=2 independent experiments for western blotting, n=3 independent experiments for immuno-
ﬂuorescence assay). Standard t-tests were used for statistical analyses of immunoﬂuorescence data; **P<0.01). (E) Effect of XPF knockdown on the
survival of cells treated with CPT in the presence or absence of ABT-888. U2OS cells transfected with XPF siRNA or negative siRNA for 48h were
treated with CPT for 30min in the absence or presence of ABT-888 (0.5mM). Cells were cultured for 10 days following drug removal to allow colony
formation. The SF of untreated cells transfected with negative siRNA (Neg siRNA) was deﬁned as 100%. Data are mean values±SD (n=3
independent experiments).
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XPF (Figure 6E). These results demonstrate that ABT-
888 further enhances the killing of XPF–ERCC1-deﬁcient
cells in response to CPT.
Involvement of XPF–ERCC1 in the
replication-independent cH2AX induced
by ABT-888 in CPT-treated cells
Next we wished to determine the gH2AX response as a
function of DNA replication in XPF-knockdown cells in
the absence or presence of ABT-888. As in Figure 3, EdU
co-staining was used to differentiate the non-replicating
and replicating cells. XPF siRNA reduced the gH2AX
enhancement by ABT-888 in both cell populations
(Figure 7A). Further analyses of gH2AX levels in individ-
ual cells also showed that XPF siRNA reduced gH2AX
levels enhancement both in the EdU negative and EdU
positive cells (Figure 7B). Four-way ANOVA analyses
of gH2AX data from two independent experiments
demonstrated signiﬁcant difference of gH2AX enhance-
ment between XPF siRNA- and Negative siRNA-
transfected cells (P<0.05). The dependence on XPF was
further analyzed in the EdU negative cells (Fig. 7C). In
those cells, XPF knockdown signiﬁcantly attenuated the
gH2AX response to ABT-888. Together these results dem-
onstrate the involvement of XPF–ERCC1 both in
replication-dependent and independent gH2AX activation
by PARP inhibition in CPT-treated human cells.
DISCUSSION
The present study provides new insights into alterna-
tive pathways for the repair of Top1-induced DNA
damage in human cells and on the rationale for combining
Top1 and PARP inhibitors. Our experiments demon-
strate that ABT-888 enhances the DNA damaging
activities of CPT (cytotoxicity, DNA breaks, gH2AX in-
duction) at concentrations where ABT-888 does not
have detectable effects on its own. Our results are con-
sistent with the reported effects of other PARP
inhibitors (NU1025, AG14361) in combination with
CPT derivatives (25,27) and provide mechanistic insights
for the recently initiated clinical trials combining
topotecan or irinotecan and veliparib (ABT-888). Our
data also suggest the usefulness of gH2AX as a clinical
pharmacodynamic biomarker in such combination
therapies (44,56).
Although PARP has been reported to directly activate
Top1 (57–59), our study shows that ABT-888 increases the
cytotoxicity of CPT without affecting the levels of Top1cc
(Figure 2). Similarly, another PARP inhibitor, AG14361
was reported to synergize with topotecan without affecting
the Top1cc levels (27). Noticeably, our study also shows
that PARP inhibition increases the levels of ‘frank breaks’
(i.e. non-Top1-associated) (Figures 1 and 2), which is in
agreement with independent studies with different PARP
inhibitors (24,27). Our interpretation is that these breaks
correspond to new ‘repair lesions’ introduced by endo-
nucleases such as XPF–ERCC1 in order to remove the
Top1cc and process the damaged DNA into a suitable
substrate for HR (Figure 8).
Our data indicate that PARP acts downstream from the
proteasome. Indeed, ABT-888 was unable to enhance the
gH2AX response to CPT when cells were simultaneously
treated with MG-132 (Supplementary Figure S3). Our
results along with recent studies (46,48,60,61) place the
proteasome as an early effector in the repair of Top1cc
(Figure 8). It is plausible that Top1, which is a 100kDa
polypeptide encircling the DNA to which it is covalently
bound (5) needs to be proteolyzed for the repair enzymes
(including TDP1) to access the broken DNA ends (13,62–
64). PARP is also a known cofactor of XRCC1, and
XRCC1 is an established repair factor for Top1cc
(54,63,65,66). XRCC1 forms repair complexes with
TDP1 (53,63,67), and PARP1 knockout cells tend to be
deﬁcient in TDP1 activity [Figure 7 in (2)]. Together with
our ﬁnding that ABT-888 failed to enhance the gH2AX
and cytotoxic responses to CPT in TDP1
 /  cells (53) (see
Figure 5), these results suggest that PARP functions
together with TDP1 in a common repair pathway
(Figure 8A).
The present study provides the ﬁrst evidence for a role
of XPF–ERCC1 in the repair of Top1-induced
DNA damage in human cells (Figure 8). This conclusion
is consistent with genetic data in budding yeast where
inactivation of Rad1–Rad10 (the yeast XPF–ERCC1
orthologs) sensitizes cells to CPT, especially when TDP1
is also inactivated (17,32) [reviewed in (2)]. Thus, we
propose that XPF–ERCC1 functions as an alterna-
tive repair pathway besides the PARP-TDP1 pathway
in mammalian cells (Figure 8). This can explain why
inactivation of XPF–ERCC1 can further increase the
cytotoxicity of ABT-888 in CPT-treated cells
(Figure 6E). However, because we also found that inacti-
vation of XPF–ERCC1 inhibits the gH2AX response
(Figure 6A–D), it is plausible that XPF–ERCC1 repairs
Top1cc by cleaving the DNA upstream from the Top1cc
and generating ‘frank breaks’ (see beginning of
‘Discussion’ section). These breaks could then be respon-
sible for the XPF–ERCC1-dependent activation of
gH2AX (Figure 8B).
Our data suggest that XPF–ERCC1 is involved not only
in the repair of replication-associated DNA damage but
also in the repair of replication-independent DNA damage
generated by Top1cc. This adds XPF–ERCC1 to the
cellular responses to Top1cc-induced transcription-
associated damage in addition to RNA polymerase II
hyperphosphorylation, BRCA1-dependent proteolysis of
Top1 (8), RNaseH1-dependent DSB induction with
ATM activation (12) and altered RNA splicing (68). The
increase in DSB and gH2AX by ABT-888 in normal per-
ipheral lymphocytes raises the question as to whether the
synergistic effect of PARP inhibitors is selective for cancer
cells. The ongoing clinical trials with veliparib in associ-
ation with topotecan or irinotecan should provide an
answer to this question. Finally, our experiments suggest
that maximum beneﬁt for combining PARP and Top1
inhibitors might be achieved in tumors with XPF–
ERCC1 deﬁciency.
3616 Nucleic Acids Research, 2011,Vol.39, No. 9Figure 7. XPF–ERCC1-dependent gH2AX enhancement by ABT-888 in non-replicating cells. U2OS cells were transfected with XPF siRNAs or
control siRNAs (Neg siRNA). Two days later, the cells were labeled with EdU and treated with CPT (1mM) for 30min in the absence or presence of
ABT-888 (0.5mM). Cells were ﬁxed and stained for immunoﬂuorescence assays. (A) Representative confocal microscopy images (red signal: EdU;
green signal: gH2AX; blue signal: DAPI to stain nuclei); bar=8mm. (B) Quantitation of gH2AX signals in individual cells (represented as scattered
dots) from one representative experiment; Mean values±SEM are shown as red lines. Numbers above each cluster indicate the number of cells
counted. Standard t-tests were used for statistical analyses of the data from the representative experiment, **P<0.01; NS, no signiﬁcant difference.
(C) XPF-dependent effect of ABT-888 in non-replicating (EdU negative) cells. Percentages of gH2AX-positive cells were scored based on drug
treatment and XPF knockdown. The number of gH2AX positive cells and total number of cells scored in each group are indicated above each bar.
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